New Chronic Hives Drug Showed Promise in Phase 3 Trials

Adults with hives resistant to antihistamines may soon have a new treatment option for symptoms.

Updated on Sept. 28, 2026 in Allergies

Row of glass pharmaceutical vials on a brushed-steel laboratory surface, captured in soft clinical lighting. — Celldex Therapeutics' experimental drug barzolvolimab showed significant efficacy in global phase 3 clinical trials for patients with chronic spontaneous urticaria. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical treatments for chronic conditions generally improve patient long-term health outcomes?

In recent global phase 3 clinical trials, the experimental drug barzolvolimab demonstrated significant efficacy for patients with chronic spontaneous urticaria. The drug, developed by Celldex Therapeutics, aimed to alleviate hives and swelling in adults who do not respond to standard H1-antihistamines.

Why it matters

Chronic spontaneous urticaria is often difficult to manage when antihistamines fail, leading to persistent hives and discomfort. This trial suggests a potential new path for symptom control in patients who previously had few treatment alternatives.

In randomized, placebo-controlled phase 3 trials of 1,939 adults, barzolvolimab achieved primary endpoints in urticaria activity scores by Week 12. Complete response rates reached up to 45.7% compared to 12.6% for placebo, with angioedema resolution occurring in up to 74.3% of treated patients.

The players

Celldex Therapeutics

A biotechnology company focused on developing monoclonal antibody-based therapeutics for inflammatory diseases.

FDA

The federal agency responsible for overseeing the safety and efficacy of medical products in the United States.

The details

The trials evaluated barzolvolimab's effect on chronic spontaneous urticaria, a condition marked by spontaneous hives and swelling. Participants received either the drug or a placebo for 24 weeks to assess changes in urticaria activity scores and the resolution of angioedema. The medication was reported as well-tolerated throughout the initial 24-week placebo-controlled study period.

Week 12 marked the primary endpoint assessment for urticaria activity scores.
Week 24 served as the conclusion of the initial placebo-controlled study phase.
2027 is the projected year for a biologics license application submission to the FDA.

Allergies
Sept. 22
Severe Alopecia Treatment Guidelines Were Standardized
Cancer
Sept. 22
FDA Requested More Survival Data for Tovecimig
Arthritis
Sept. 28
Psoriasis Drug zasocitinib Met Phase 3 Study Goals

Health Landscape

The development of barzolvolimab marks a potential shift for patients with chronic spontaneous urticaria who remain symptomatic despite using standard antihistamine therapies. It follows a broader trend in immunology research focusing on targeted monoclonal antibodies to address recalcitrant inflammatory conditions.

If you struggle with persistent hives that do not respond to over-the-counter antihistamines, these findings offer a potential future treatment category to track. It is worth discussing with your doctor whether your current care plan adequately manages your symptoms or if new research options might be relevant.

The takeaway

While these trial results demonstrate promise for treating difficult cases of chronic hives, the drug is not yet available to the public. If you currently experience chronic symptoms, maintain a detailed diary of your flare-ups and consult your physician to optimize your current treatment plan.